Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia

Montoya, Nora G.; Gómez, Liliana; Vélez, Mauricio; Rosselli, Diego

doi:10.1016/s0121-8123(11)70060-3

Cited by 8 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…RA generates a significant economic burden for health systems, due to direct costs (healthcare and drugs) and indirect costs (productive losses), with an estimated yearly cost of USD 41,000 per patient in the United States, and this is expected to increase due to increased use of biological drugs, comorbidities, increased age of the population, and widespread physical inactivity [ 15 , 16 ]. In Colombia, Montoya et al calculated the direct healthcare costs for RA patients in Medellin between 2007 and 2009, finding a mean of USD 8178 USD per year, 87.9% of which was pharmaceutical expenditures, in particular drugs of biological origin [ 17 ]. However, there is a gap in knowledge related to the economic evidence in the current attention of RA, considering the implementation of price drug regulation, availability of treatments in the last years, and changes of attention models in the Colombian healthcare system.…”

Section: Introductionmentioning

confidence: 99%

Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib

et al. 2020

View full text Add to dashboard Cite

Introduction/objectives The objective of this study is to describe the treatment patterns and use of healthcare resources in a cohort of Colombian patients with rheumatoid arthritis (RA) treated with biological disease-modifying antirheumatic drugs (bDMARDs) or tofacitinib. Method This is a descriptive study from a retrospective cohort of patients diagnosed with RA who were treated with bDMARDs or tofacitinib after failure of conventional DMARDs (cDMARDs) or first bDMARD. Patients who were receiving pharmacological treatment between 01 January 2014 and 30 June 2018 were included. The analysis is through the revision of claim database and electronical medical records. Demographic and clinical data were collected. The costs of healthcare resources were estimated from the billing expense of healthcare service provider. Results We evaluated 588 RA patients on treatment with bDMARDs (n = 505) or tofacitinib (n = 83), most of them were in combination with cDMARDs (85.4%). The 88.1% were females and mean age was 57.3 ± 12.5 years. The median evolution of RA since diagnosis was 9 years (IQR:4–17.2). The mean duration of use during follow-up of the bDMARDs or tofacitinib was similar, with a mean of 9.8 ± 1.9 months. It was identified that 394 (67.0%) discontinued therapy. The average annual direct cost of care per patient was USD 8997 ± 2172, where 97.2% was due to drug costs. The average annual cost of treatment per patient with bDMARDs was USD 8604 and tofacitinib was USD 6377. Conclusions In the face of a first failure of cDMARD, bDMARDs are frequently added. A high frequency of patients do not persist treatment during the first year of follow-up. The pharmacological treatment is the most representative cause of healthcare costs. Key Points• Rheumatoid arthritis is a disease with a high burden of comorbidities, complications, and worse health-related quality of life and is associated with elevated healthcare costs.• The biological disease-modifying antirheumatic drugs or tofacitinib medications are indicated for those with significant progression of the disease and when there is a need for alternatives to achieve low levels of activity and remission.• Patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs or tofacitinib represent a significant economic burden to the health system, especially in the costs derived from pharmacological treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib

et al. 2020

View full text Add to dashboard Cite

show abstract

“…bIbLIOGRAFíA co y un tratamiento lo más precoz posible. Alrededor de 0.6% a 1% de la población mundial se aqueja de esta enfermedad y afecta a todos los grupos étnicos, preferentemente a mujeres entre los 40 a 50 años de vida 2,3,[11][12][13][14][15] .…”

Section: Resultsunclassified

Nivel de conocimiento sobre la artritis reumatoi- de en la población adulta del Paraguay de febrero a marzo del 2022

Cuellar,

Ibarra,

González

et al. 2023

Rev. parag. reumatol.

View full text Add to dashboard Cite

La artritis reumatoide es una enfermedad inflamatoria crónica que afecta las articulaciones, con una etiología poco conocida. Alrededor del 1% de la población mundial padece esta enfermedad sin distinción de etnias, con preferencia en mujeres de 40 a 50 años de edad. Objetivo: Describir el nivel de conocimiento sobre la artritis reumatoide en adultos del Paraguay de febrero a marzo del 2022. Métodos: se diseñó un estudio de tipo observacional, descriptivo, de corte transversal, se realizó una encuesta a personas residentes en Paraguay. Se aplicó un muestreo no probabilístico, de tipo bola de nieve para la recolección de datos que consistió en una encuesta online difundida por vía WhatsApp. Resultados: se analizó 103 encuestas recolectadas de ciudades urbanas y rurales del Paraguay sobre el conocimiento de la artritis reumatoide, la mediana de edad fue de 23 años +/- RI 12, el máximo de edad fue de 78 años y el mínimo fue de18 años. En cuanto al conocimiento de la enfermedad, el 67,6%conoce sobre la enfermedad, el 80% la definieron correctamente; el 81% conoce los síntomas y el 54% conoce las causas de la artritis reumatoide. Conclusiones: se debe tomar importancia y dar una mirada a la cuestión del conocimiento que la población posee acerca de la artritis reumatoide, a pesar de que existe un nivel mayoritario de conocimiento aún, sigue persistiendo un desconocimiento de cierta proporción de individuos, por ende, la integración de ciertos métodos didácticos o un plan que facilite el aprendizaje de la sociedad sobre este tema sería un objetivo y una meta fundamental.

show abstract

“…Among these, 351 articles were excluded after title screening and the abstract of the 784 remaining papers was assessed. Finally, 461 publications were excluded following the eligibility criteria and thus, 323 articles that had interpretable data and fulfilled the eligibility criteria were used for data extraction…”

Section: Resultsmentioning

confidence: 99%

Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review

Franco¹,

Vizcaya²

2020

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia

Cited by 8 publications

References 15 publications

Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib

Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib

Nivel de conocimiento sobre la artritis reumatoi- de en la población adulta del Paraguay de febrero a marzo del 2022

Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review

Contact Info

Product

Resources

About